These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28188101)
1. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Sun L; Ma JT; Zhang SL; Zou HW; Han CB Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Yang K; Wang YJ; Chen XR; Chen HN Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials. Li X; Wang H; Lin W; Xu Q Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic agents combined with chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: overall and histology subgroup-specific meta-analysis. Zhang L; Cao F; Wang Y; Wang S; Zhong D Oncol Res Treat; 2014; 37(12):710-8. PubMed ID: 25531716 [TBL] [Abstract][Full Text] [Related]
6. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142 [TBL] [Abstract][Full Text] [Related]
9. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials. Yu S; Xu Q; Yuan Y; Li X; Cai H Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336 [TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs. Sheng Z; Zhang Y Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315 [TBL] [Abstract][Full Text] [Related]
12. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502 [TBL] [Abstract][Full Text] [Related]
13. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials. Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review. Sheng J; Yang YP; Yang BJ; Zhao YY; Ma YX; Hong SD; Zhang YX; Zhao HY; Huang Y; Zhang L Medicine (Baltimore); 2015 Aug; 94(31):e1282. PubMed ID: 26252298 [TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Soria JC; Mauguen A; Reck M; Sandler AB; Saijo N; Johnson DH; Burcoveanu D; Fukuoka M; Besse B; Pignon JP; Ann Oncol; 2013 Jan; 24(1):20-30. PubMed ID: 23180113 [TBL] [Abstract][Full Text] [Related]
16. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395 [TBL] [Abstract][Full Text] [Related]
17. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Zhang TT; Wang RM; Yang Z; Chen GB Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033 [TBL] [Abstract][Full Text] [Related]
19. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. Peng TR; Tsai FP; Wu TW Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]